BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 32542586)

  • 1. Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm.
    Sengar M; Jain H; Rajendra A; Rengaraj K; Thorat J
    Curr Hematol Malig Rep; 2020 Jun; 15(3):168-176. PubMed ID: 32542586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is There a Role for Chemotherapy in the Era of Targeted Therapies?
    Lee JC; Lamanna N
    Curr Hematol Malig Rep; 2020 Apr; 15(2):72-82. PubMed ID: 32107713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
    Milunović V; Mišura Jakobac K; Mandac Rogulj I; Martinović M; Radić-Krišto D; Ostojić Kolonić S
    Expert Rev Hematol; 2020 Jul; 13(7):771-779. PubMed ID: 32579408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving treatment landscape of chronic lymphocytic leukemia.
    Schiattone L; Ghia P; Scarfò L
    Curr Opin Oncol; 2019 Nov; 31(6):568-573. PubMed ID: 31593975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?
    Voorhies BN; Stephens DM
    Curr Treat Options Oncol; 2017 Feb; 18(2):12. PubMed ID: 28243993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia.
    Brown JR; Kay NE
    J Clin Oncol; 2017 Sep; 35(26):2989-2992. PubMed ID: 28742455
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
    Brown JR; Hallek MJ; Pagel JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
    Small S; Ma S
    Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment approaches in CLL: Challenges and opportunities in the elderly.
    Eichhorst B; Hallek M; Goede V
    J Geriatr Oncol; 2016 Sep; 7(5):375-82. PubMed ID: 27491497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
    Hilal T; Gea-Banacloche JC; Leis JF
    Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
    Cramer P; Langerbeins P; Hallek M
    Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
    Odetola O; Ma S
    Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Wendtner CM; Gregor M
    Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic lymphocytic leukemia therapy: new targeted therapies on the way.
    Vitale C; Burger JA
    Expert Opin Pharmacother; 2016 Jun; 17(8):1077-89. PubMed ID: 26988407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
    Bennett R; Anderson MA; Seymour JF
    J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
    Davids MS; Waweru C; Le Nouveau P; Padhiar A; Singh G; Abhyankar S; Leblond V
    Clin Ther; 2020 Oct; 42(10):1955-1974.e15. PubMed ID: 33032842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapies in Chronic Lymphocytic Leukemia: Is 2 (or 3) Better Than 1?
    Ujjani C; Cheson BD
    Cancer J; 2019; 25(6):449-454. PubMed ID: 31764127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.